National Pension Service raised its stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 1.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 935,283 shares of the medical research company’s stock after purchasing an additional 11,524 shares during the quarter. National Pension Service owned 0.16% of Edwards Lifesciences worth $79,733,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently made changes to their positions in EW. JPL Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $28,000. Hantz Financial Services Inc. boosted its position in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 164 shares in the last quarter. Dorato Capital Management acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $29,000. Finally, Rakuten Securities Inc. boosted its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 106,397 shares of company stock worth $8,848,664 over the last ninety days. Corporate insiders own 0.31% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Price Performance
NYSE:EW opened at $86.41 on Friday. The firm has a market cap of $49.76 billion, a PE ratio of 45.96, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $88.28. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $81.73 and its two-hundred day moving average price is $83.01.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Edwards Lifesciences Profile
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More
- Five stocks we like better than Edwards Lifesciences
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
